Reviews

Ticker: 533329 FV: Rs.2
52-Week H/L: Rs.252.55/160

We had recommended Indian Terrain Fashions in Volume No 34, Issue No 10 (dated Dec 25, 2017), when the scrip was trading at Rs 217. Our recommendation was backed by robust growth in topline and profitability. On the financial front, the revenue was marginally up from Rs 399.7 crore to Rs 401.45 crore in FY18. Its EBITDA for the year was muted with EBITDA margin hovering at 11.8 per cent . However, the PAT for the year declined by 7.8 per cent YoY from Rs 27.59 crore to Rs 25.44 crore. The management had estimated 20 per cent growth for the company in FY18, but the estimates were missed. This will affect the company's target of doubling the topline by FY20. The company's pace has lowered and, thereby, we expect limited upside in the stock price. Thus, we urge investors to EXIT the scrip.

Ticker: 532150 FV: Rs.10
52-Week H/L: Rs.68.35/42.20

We had recommended Indraprastha Medical Corporation in Volume No 34, Issue No 12 (dated Jan 8, 2018), when the scrip was trading at Rs 64. Our recommendation was backed by growth led by new services and technologies. For FY18, the company declared dividend  of Rs 1.5 per equity share for its shareholders. The revenue declined marginally in FY18. The operating profit and net profit were down by 7.15 per cent and 19.6 per cent , respectively, on a YoY basis. In the latest budget, the government assigned funds for the healthcare industry, yet the sector has underperformed and this company is no exception. We expect FY19 would remain flattish and hence urge investors to EXIT the scrip.